Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Blood supply

This article was originally published in The Gray Sheet

Executive Summary

FDA and the American Red Cross fail to identify a mutually acceptable system of prospective fines for future blood bank safety violations after sixteen months of negotiations related to quality assurance oversight of blood donations. According to FDA, the Red Cross has not abided by a 1993 consent decree in which it promised to make significant improvements in blood safety oversight at its national headquarters and regional facilities. On Dec. 11, the agency asked a federal court for authority to impose prospective fines against the Red Cross for future violations in order to force conformance to the consent decree...
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT015838

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel